Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.63 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21659712 | 0.89 | ESR2 (0.63) | ESR2NR1H2ABHD6GPR119ESR1 | |
| SCHEMBL31425341 | 0.89 | ESR2 (0.63) | ESR2NR1H2ABHD6GPR119ESR1 | |
| SCHEMBL22755687 | 0.88 | ESR2 (0.62) | ESR2NR1H2ABHD6GPR119ESR1 | |
| SCHEMBL31014031 | 0.88 | ESR2 (0.62) | ESR2NR1H2ABHD6GPR119ESR1 | |
| SCHEMBL14781510 | 0.87 | ESR2 (0.67) | ESR2NR1H2ABHD6GPR119ESR1 | |
| SCHEMBL17583901 | 0.87 | ESR2 (0.61) | ESR2NR1H2ABHD6GPR119DDB1 | |
| SCHEMBL5100452 | 0.86 | ESR2 (0.60) | ESR2NR1H2ABHD6GPR119ESR1 | |
| SCHEMBL22755613 | 0.85 | NR1H2 (0.63) | ESR2NR1H2ABHD6GPR119HRH3 | |
| SCHEMBL1266229 | 0.85 | NR1H2 (0.63) | ESR2NR1H2ABHD6GPR119HRH3 | |
| SCHEMBL5106572 | 0.85 | HRH3 (0.61) | ESR2NR1H2ABHD6HRH3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | ESR2 1537/4885NR1H2 46/4885ABHD6 2635/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | ESR2 1445/4885NR1H2 44/4885ABHD6 2655/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | ESR2 1537/4885NR1H2 46/4885ABHD6 2635/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ESR2 1445/4885NR1H2 44/4885ABHD6 2655/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ESR2 1445/4885NR1H2 44/4885ABHD6 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.